Vimarsana
Biggest News Aggregation in the World

Oblato Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oblato Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oblato Inc Today - Breaking & Trending Today

High-grade Glioma Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Companies to Watch Out - BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, Bristol-Myers Squibb, Laminar, Immunomic, Inovio - Vimarsana News

High-grade Glioma Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Companies to Watch Out - BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, Bristol-Myers Squibb, Laminar, Immunomic, Inovio

Published: October 25, 2023

/PRNewswire/ -- DelveInsight's High-grade Glioma Market Insights report includes a comprehensive understanding of current treatment practices, high-grade...

Source: prnewswire.com
Related Topics:
United KingdomUnited StatesPrnewswire DelveinsightShruti ThakurEli LillyCellectar BiosciencesTemodar TemodalBasilea PharmaceuticaBristol Myers SquibbMono PharmaceuticalsErimos PharmaceuticalsLaminar PharmaceuticalsOblato IncDelveinsight Business ResearchKey Glioma CompaniesSumitomo Pharma Oncology IncAlpheus Medical IncLee PharmaceuticalMerck Sharp DohmeNeonc Technologies IncDelmar PharmaceuticalsXynomic Pharmaceuticals IncMarket ResearchCelldex TherapeuticsNuvation Bio Inc
Significant Positive Shift in the Glioma Market with 13% CAGR During the Study Period (2019-2032) Expected by Analysts at DelveInsight - Vimarsana News

Significant Positive Shift in the Glioma Market with 13% CAGR During the Study Period (2019-2032) Expected by Analysts at DelveInsight

Published: May 1, 2023

/PRNewswire/ -- DelveInsight's Glioma Market Insights report includes a comprehensive understanding of current treatment practices, glioma emerging drugs,...

Source: prnewswire.com
Related Topics:
United KingdomUnited StatesAvastin GenentechDaiichi SankyoShruti ThakurOlaptesed PegolTemodar Temodal MerckEli LillyDenovo BiopharmaLaminar PharmaceuticalsMarket ResearchLee PharmaceuticalClinical DevelopmentKey Glioma CompaniesRoche Incyte CorporationOblato IncEuropean Association Of NeuroAmerican Society Of Therapeutic RadiologyEpitopoietic Research CorporationIncyte CorporationInovio PharmaceuticalsHealthcare ServicesKey CompaniesAmerican Society Of Clinical OncologyDelmar Pharmaceuticals
Oblato Announces the First Enrollment in a Phase 1 Clinical Trial for an Oral Formulation of OKN-007 in Recurrent High-Grade Glioma Patients in the USA - Vimarsana News

Oblato Announces the First Enrollment in a Phase 1 Clinical Trial for an Oral Formulation of OKN-007 in Recurrent High-Grade Glioma Patients in the USA

Published: April 21, 2023

/PRNewswire/ -- Oblato, Inc. (the Company), a subsidiary company of HLB Therapeutics in Korea, has announced today the first enrollment for recurrent...

Source: prnewswire.com
Related Topics:
South KoreaUnited StatesNew JerseyChong AhnPrnewswire Oblato IncOblato IncProvidence Saint John Cancer InstituteHenry Ford Health SystemProvidence Saint JohnCancer InstituteNorton HealthcareHenry Ford HealthHealth Care Amp HospitalsMedical Pharmaceuticals Pharmaceuticals Clinical Trials Amp Medical Discoveries
Oblato announces that it has completed enrollment of patients for the Phase 2 recurrent glioblastoma multiforme clinical trial in the US - Vimarsana News

Oblato announces that it has completed enrollment of patients for the Phase 2 recurrent glioblastoma multiforme clinical trial in the US

Published: October 25, 2022

/PRNewswire/ -- Oblato, Inc. (the Company) a subsidiary company of HLB Therapeutics in Korea, announced today that the enrollment of recurrent glioblastoma...

Source: prnewswire.com
Related Topics:
United StatesSouth KoreaNew JerseyChong AhnOblato IncStephenson Cancer CenterUniversity Of Oklahoma Health Sciences CenterPrnewswire Oblato IncOklahoma Health Sciences Center
Low-grade Glioma Market to Boost at a CAGR of 3.4% by 2032 - Vimarsana News

Low-grade Glioma Market to Boost at a CAGR of 3.4% by 2032

Published: September 21, 2022

/PRNewswire/ -- DelveInsight's Low-grade glioma Market Insights report includes a comprehensive understanding of current treatment practices, low-grade glioma...

Source: prnewswire.com
Related Topics:
United StatesShruti ThakurBasilea PharmaceuticaRoche IncytePemazyre PemigatinibEli LillyDabrafenib TrametinibLee PharmaceuticalMerck CoOncosynergy IncHealthcare Due Diligence ServicesAgios PharmaceuticalsBexion Pharmaceuticals IncNeonc Technologies IncKey Glioma CompaniesAmerican SocietyOblato IncMarket ResearchKey CompaniesDelveinsight Business ResearchMarket InsightsLow Grade Glioma MarketDay One BiopharmaceuticalsAnheart TherapeuticsSpringworks Therapeutics